The Extraordinary General Meeting decided upon a rights issue to existing shareholders in which three (3) existing shares entitle the holder to subscription for one (1) new share at a subscription price of SEK 4.50/ share. The share capital could increase by a maximum of SEK 2,104,100.80 through the issuance of up to 5,260,252 shares. Timetable for new issue Nov. 25, 2013 Last trading day for Genovis share, including subscription rights for new issue. Nov. 28, 2013 Record date for participation in the new issue; shareholders registered in Genovis’ share register on this day receive subscription rights for participation in the new issue. Dec. 2 – Dec. 16, 2013 Subscription period. Subscription with preferential rights through cash payment during the subscription period. Shareholders may report their intention to subscribe throughout the subscription period. The Extraordinary General Meeting resolve to authorize the Board, provided that the rights issue for a maximum of 5,260,252 shares is fully subscribed, on one or more occasions, to decide on the issuance of a total of a maximum of 1,350,000 shares in the Company with or without preferential rights for the Company?s shareholders. The subscription price will be four Swedish kronor and fifty öre (SEK 4.50), payment for subscribed shares shall be made in cash, and the Board will have the option to permit set-offs retroactively. This authorization will be valid for the period ending on January 20, 2014. The reason for any deviation from shareholders? preferential rights is to be able to take advantage of attracting interest from potential underwriters within the framework for issued underwriting guarantees. For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com ABOUT GENOVIS Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00
COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING FOR GENOVIS
Top 10 Most Recent News Articles
Antheia Secures $80M for Critical Medicine Onshoring
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Lundbeck's Board Leadership Transitions into New Era
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
UEG's New Advisory Board: Elevating Patient Voices
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Faith and Resilience in China: The Legacy of the Long March
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue ReadingTop 5 Most Recently Viewed Articles
Modine Expands Manufacturing Capacity with New Calgary Facility
Modine Expands Manufacturing Capacity in Calgary Modine (NYSE: MOD), a prominent player in thermal management technology, has proudly opened a new state-of-the-art facility spanning 23,200m² (~250,000ft²) to enhance support for the rapidly increasing demand from data centers, especially within the hyperscale market. This facility is dedicated to the production of...
Continue Reading
Choice Hotels Champions Wildfire Relief with Donation Match Program
Choice Hotels Champions Wildfire Relief with Donation Match Program In a heartfelt initiative, Choice Hotels International, Inc. (NYSE: CHH) has launched a campaign aimed at providing critical support to those affected by recent California wildfires. This effort focuses on empowering Choice Privileges members to contribute to the relief while amplifying their donations...
Continue Reading
APR Corp. Elevates K-Beauty Tech at CES 2025 for Global Reach
APR Corp. Unveils Ambitious Plans for CES 2025 APR Corp. is set to make significant waves in the global beauty market by returning to CES for a second year, aiming to expand its presence internationally. Building on its successful launch at CES 2024, the beauty tech innovator is gearing up for CES 2025 with exciting new developments. Showcasing Innovative Beauty...
Continue Reading
Asia's B2B Payment Risks: Strain Lurks Beneath Stability
Behind Asia's Facade of Stability Smile and wave, folks, because Asia's B2B credit scene ain't as rosy as the headlines might want you to believe. Sure, on the surface, things look stable, but dig a little deeper and there’s a whole heap of troubles brewing, especially for the smaller fry. It’s like watching a family portrait while the kids are bickering behind the...
Continue Reading
CYIOS Corporation Strengthens Investor Relations with New Partner
CYIOS Corporation Engages Atlanta Capital Partners for IR Strategy CYIOS Corporation LLC (OTC: CYIO) is making strides in its investor relations approach by hiring Atlanta Capital Partners, LLC. This strategic move aims to enhance CYIOS's visibility in the financial market and streamline communications within the investment community. Introducing Atlanta Capital Partners...
Continue Reading